In an engineered world, who benefits from biological diversity?
By Molly Bond and Deborah Scott,
The Guardian
| 12. 22. 2016
Outside the conference hall of the Moon Palace, a luxury Cancun resort, warm waves lapped white sands, bathed in a pink Mexican sunset. Inside, close to two hundred delegates to the United Nations’ 2016 biodiversity conference huddled around a doorway, desperate to get into a windowless room for the final evening’s negotiating session. In the end, most of the crowd made it into room, to witness twenty or so country delegates hammer out compromise text late into the night. This wasn’t what they had expected from a UN summit. But the issue under discussion – synthetic biology – is an unusual topic.
Synthetic biology is often described as the application of engineering principles to biology. Some see it a fundamentally new approach to biology; others as the next stage of biotechnology; and others as simply an exercise in rebranding. As social scientists researching this field, we’ve seen the confusion of synthetic biologists as to why a treaty about biodiversity is attempting to govern their research.
The reason lies in the broad mandate of the UN’s convention on biological diversity...
Related Articles
By Katherine Long, Ben Foldy, and Lingling Wei, The Wall Street Journal | 12.13.2025
Inside a closed Los Angeles courtroom, something wasn’t right.
Clerks working for family court Judge Amy Pellman were reviewing routine surrogacy petitions when they spotted an unusual pattern: the same name, again and again.
A Chinese billionaire was seeking parental...
By Sarah A. Topol, The New York Times Magazine | 12.14.2025
The women in House 3 rarely had a chance to speak to the women in House 5, but when they did, the things they heard scared them. They didn’t actually know where House 5 was, only that it was huge...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...